Aligos Therapeutics, Inc. Common Stock vs. Immunovant, Inc. Common Stock
ALGS
Aligos Therapeutics, Inc. Common Stock
$7.65 +36.85%
VS IMVTImmunovant, Inc. Common Stock
$39.89 -0.15%
Immunovant, Inc. Common Stock (IMVT) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ALGS | IMVT | |
|---|---|---|
| Market Cap | $47.77 million | $8.24 billion |
| Net Income (TTM) | — | $-538,217,000 |
IMVT leads on 1 of 1 size & scale factors.
Valuation
| ALGS | IMVT | |
|---|---|---|
| Price / Book | — | 11.20 |
ALGS and IMVT split the valuation factors evenly.
Profitability
| ALGS | IMVT | |
|---|---|---|
| Return on Equity | — | -73.19% |
ALGS and IMVT split the profitability factors evenly.
Risk & Sentiment
| ALGS | IMVT | |
|---|---|---|
| Short Interest | 36.27% | 0.15% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALGS overview, ALGS financials, IMVT overview, IMVT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.